SpinalCyte, LLC Announces Publication in Global Spine Journal, “Cell Therapy with Human Dermal Fibroblasts Enhances Intervertebral Disc Repair and Decreases Inflammation in the Rabbit Model”

HOUSTON--()--SpinalCyte, LLC, a Texas-based tissue engineering technology company focused on regrowth of the spinal disc nucleus using Human Dermal Fibroblasts (HDFs), today announced the publication of its discovery surrounding use of HDFs for regrowth and repair of the intervertebral disc in the April 2016 Edition, Issue 02, Volume 06 of the Global Spine Journal. See a link to the article: https://www.thieme-connect.com/products/ejournals/html/10.1055/s-0036-1582391

Led by renowned researcher Howard An, M.D., the team comprised Ana Chee, Peng Shi, Thomas Cha, Ting-Hsien Kao, Shu-Hua Yang, Jun Zhu, Ding Chen, and Yejia Zhang. “We are proud of the research conducted by this dedicated team of scientists and we are encouraged by the acceptance of this article for publication after a rigorous peer review process,” commented Dr. An.

“This is our second article to be accepted for publication on our technology and we are proud of this scientific team and the thoroughness of their research,” said Pete O’Heeron, Chief Executive Officer for SpinalCyte.

About SpinalCyte, LLC

Based in Houston, Texas, SpinalCyte, LLC is a tissue engineering technology company founded for the purpose of developing an innovative and autologous solution for spinal nucleus replacement using human dermal fibroblasts. The goal of SpinalCyte is to develop a cartilage regeneration technology using dermal cells. To date, SpinalCyte has been funded entirely by angel investors.

Contacts

SpinalCyte, LLC
Pete O’Heeron, CEO, 281.461.6211
pete@spinalcyte.com

Contacts

SpinalCyte, LLC
Pete O’Heeron, CEO, 281.461.6211
pete@spinalcyte.com